Anuncio • Feb 17
Sartorius Aktiengesellschaft, Annual General Meeting, Mar 26, 2026 Sartorius Aktiengesellschaft, Annual General Meeting, Mar 26, 2026, at 12:00 W. Europe Standard Time. Anuncio • Feb 07
Sartorius Aktiengesellschaft announces Annual dividend, payable on March 31, 2026 Sartorius Aktiengesellschaft announced Annual dividend of EUR 0.7400 per share payable on March 31, 2026, ex-date on March 27, 2026 and record date on March 30, 2026. Anuncio • Feb 05
Sartorius AG Provides Earnings Guidance for the Fiscal Year 2026 Sartorius AG provided earnings guidance for the fiscal year 2026. For the year, the company expects its profitable growth trajectory to continue, with a continued positive development in the Bioprocess Solutions Division and a recovery in the Lab Products & Services Division. Anuncio • Jan 28
Sartorius Aktiengesellschaft to Report Fiscal Year 2025 Final Results on Feb 16, 2026 Sartorius Aktiengesellschaft announced that they will report fiscal year 2025 final results at 12:00 PM, Central European Standard Time on Feb 16, 2026 Anuncio • Jan 16
Sartorius Expands Bio-Circular Product Offering for More Sustainable Bioprocesses Sartorius AG expanded bio-circular product offering for more sustainable bioprocesses. Further production hubs in Germany and Tunisia now certified by International Sustainability and Carbon Certification. Certified raw materials significantly reduce dependence on fossil-based plastics. Bio-circular filters and additional single-use fluid management technologies now available for biopharma manufacturers. Certified production network spans sites in Germany, Tunisia, France and the UK. With ISCC Plus certification now extended to its sites in Gottingen, Germany, and M'Hamdia, Tunisia, the company can use certified renewable raw materials in additional product lines, reducing the share of fossil-based plastics while ensuring full compatibility with existing bioprocesses. ISCC Plus is a global standard for renewable and recycled raw materials that ensures transparent and traceable sourcing and compliance across the value chain based on a mass-balance system. At its Gottingen headquarters, Sartorius will produce the PFAS-free filter Sartopore Evo using ISCC Plus-certified materials. In M'Hamdia, selected Flexsafe bags will be manufactured with certified second generation feedstock. The use of ISCC Plus-certified material enables a reduction of fossil-based compounds by around 70% in the Flexsafe film and by an average 40-60% in Sartopore Evo filters. Earlier in 2025, Sartorius achieved ISCC Plus certification for its sites in Aubagne, France, and Stonehouse, United Kingdom, covering its Ambr bioreactor vessels, Vivaflow filters, and selected Flexsafe bags for the manufacture of biopharmaceutical. The company plans to expand the use of certified renewable raw materials across its global production network. Anuncio • Oct 17
Sartorius Aktiengesellschaft Revises Financial Guidance for the Year 2025 Sartorius Aktiengesellschaft revised financial guidance for the year 2025. Based on the year-to-date results and taking into account the anticipated impact of existing tariffs, the contributions from the MATTEK acquisition, as well as the strong basis for comparison in the fourth quarter of 2024, management further sharpens its full-year guidance for the Group and both divisions. The company now expects sales revenue growth at Group level of around 7% (previously: around 6% organic growth with a forecast range of about plus/minus two percentage points). This includes an inorganic growth contribution of around 0.3%. Anuncio • Apr 17
Sartorius Aktiengesellschaft Provides Earnings Guidance for the Fiscal 2025 Sartorius Aktiengesellschaft provided earnings guidance for the fiscal 2025. For the period, Based on the first quarter results and the expected good underlying market development, management projects sales revenue growth of around 6% for the Group, around 7% for the Bioprocess Solutions division and around 1% for Lab Products & Services for 2025. Due to the continued above-average volatility, the company currently anticipates a forecast range of about plus/minus two percentage points respectively. Anuncio • Mar 29
Sartorius Ag Approves Ordinary Dividend, Payable on April 1, 2025 Sartorius AG at its AGM held on March 27, 2025, approved the dividend of 0.73 euros per ordinary share. The total amount disbursed will be 50.7 million euros, with the dividend to be paid out to shareholders on April 1, 2025. Anuncio • Feb 18
Sartorius Aktiengesellschaft, Annual General Meeting, Mar 27, 2025 Sartorius Aktiengesellschaft, Annual General Meeting, Mar 27, 2025. Anuncio • Feb 09
Sartorius AG Proposes Ordinary Dividend for Fiscal 2024, Payable on April 1, 2025 The Supervisory Board of Sartorius AG resolved at its meeting held on February 7, 2025 to approve the recommendation of the Executive Board to submit a proposal to the Annual General Meeting on March 27, 2025, to pay a dividend of EUR 0.73 per ordinary share for fiscal 2024, the same amount as for the previous year. The dividend will be paid on April 1, 2025. Anuncio • Nov 16
Sartorius Aktiengesellschaft to Report Fiscal Year 2024 Results on Jan 28, 2025 Sartorius Aktiengesellschaft announced that they will report fiscal year 2024 results on Jan 28, 2025 Anuncio • Sep 19
Labforward GmbH acquired LabTwin GmbH from Sartorius Aktiengesellschaft (XTRA:SRT3). Labforward GmbH acquired LabTwin GmbH from Sartorius Aktiengesellschaft (XTRA:SRT3) on September 17, 2024. Sartorius will become a shareholder in labforward GmbH post the transaction. The merged company will be led by Joerg Hoffmann of labforward GmbH. The future headquarters will be the previous location of LabTwin in Berlin.
Labforward GmbH completed the acquisition of LabTwin GmbH from Sartorius Aktiengesellschaft (XTRA:SRT3) on September 17, 2024. Anuncio • Feb 03
Sartorius Aktiengesellschaft to Report Fiscal Year 2023 Final Results on Feb 16, 2024 Sartorius Aktiengesellschaft announced that they will report fiscal year 2023 final results at 7:00 AM, Central European Standard Time on Feb 16, 2024 Anuncio • Jan 18
Sartorius Aktiengesellschaft to Report Fiscal Year 2023 Results on Jan 26, 2024 Sartorius Aktiengesellschaft announced that they will report fiscal year 2023 results at 7:00 AM, Central European Standard Time on Jan 26, 2024 Anuncio • Oct 13
Sartorius Ag Lowers Earnings Forecast for the Fiscal Year 2023 SARTORIUS AG lowered earnings forecast for the fiscal year 2023. For the year, Group sales revenue is expected to decline by around 17 percent; excluding Covid-19-related business, revenue would decline by around 12% (previously: sales revenue decline in the low to mid-teens percentage range; excluding Covid-19-related business, decline in the mid to high single-digit percentage range). Acquisitions are still expected to contribute around 2 percentage points to the sales revenue development. Anuncio • Jan 27
Sartorius Aktiengesellschaft Provides Revenue Guidance for the Full Year 2023 Sartorius Aktiengesellschaft provided revenue guidance for the full year 2023. Consolidated sales revenue is expected to increase by an amount in the low single-digit percentage range. Excluding the Covid-19-related business, the increase would be in the high single-digit percentage range. Acquisitions are anticipated to contribute around 1% point to growth. Anuncio • Jan 04
Sartorius Announces Management Changes for Sartorius North America Sartorius announced Maurice Phelan has assumed the role of President of Sartorius North America. He succeeds Mary Lavin, who has retired after nearly 35 years. Sartorius North America, headquartered in Bohemia, New York, currently employs more than 3,000 employees across 17 sites in the United States and Canada. Mr. Phelan has spent many years in the industry and recently rejoined Sartorius from Repligen, where he was Vice President of Fluid Management. Before that, he served as Head of Operations of the Sartorius site in Marlborough, Massachusetts. Previously, he held leadership roles at GE Healthcare and Merck Millipore. Mr. Phelan holds degrees in chemistry and experimental physics from the National University of Ireland. Anuncio • Oct 20
Sartorius Aktiengesellschaft to Report Fiscal Year 2022 Final Results on Feb 17, 2023 Sartorius Aktiengesellschaft announced that they will report fiscal year 2022 final results on Feb 17, 2023 Major Estimate Revision • Jul 28
Consensus forecasts updated The consensus outlook for 2022 has been updated. 2022 EPS estimate increased from €9.25 to €10.20. Revenue forecast steady at €4.16b. Net income forecast to grow 35% next year vs 13% growth forecast for Medical Equipment industry in Germany. Consensus price target down from €416 to €404. Share price was steady at €389 over the past week. Reported Earnings • Jul 22
First quarter 2022 earnings released First quarter 2022 results: EPS: €3.01. Revenue: €1.02b (up 30% from 1Q 2021). Net income: €205.6m (up 128% from 1Q 2021). Profit margin: 20% (up from 11% in 1Q 2021). Over the next year, revenue is forecast to grow 16%, compared to a 7.9% growth forecast for the industry in Germany. Price Target Changed • Jul 22
Price target decreased to €404 Down from €444, the current price target is an average from 17 analysts. New target price is 5.1% above last closing price of €385. Stock is down 21% over the past year. The company is forecast to post earnings per share of €9.55 for next year compared to €4.66 last year. Price Target Changed • Jul 12
Price target decreased to €416 Down from €470, the current price target is an average from 17 analysts. New target price is 15% above last closing price of €363. Stock is down 26% over the past year. The company is forecast to post earnings per share of €8.83 for next year compared to €4.66 last year. Buying Opportunity • May 31
Now 21% undervalued after recent price drop Over the last 90 days, the stock is down 1.1%. The fair value is estimated to be €448, however this is not to be taken as a buy recommendation but rather should be used as a guide only. For the next 3 years, revenue is forecast to grow by 10% per annum. Earnings is also forecast to grow by 11% per annum over the same time period. Reported Earnings • Apr 27
First quarter 2022 earnings: EPS and revenues exceed analyst expectations First quarter 2022 results: EPS: €3.00. Revenue: €1.02b (up 30% from 1Q 2021). Net income: €205.6m (up 151% from 1Q 2021). Profit margin: 20% (up from 10% in 1Q 2021). Revenue exceeded analyst estimates by 7.8%. Earnings per share (EPS) also surpassed analyst estimates by 41%. Over the next year, revenue is forecast to grow 15%, compared to a 11% growth forecast for the industry in Germany. Upcoming Dividend • Mar 21
Upcoming dividend of €1.25 per share Eligible shareholders must have bought the stock before 28 March 2022. Payment date: 30 March 2022. Payout ratio is a comfortable 27% and this is well supported by cash flows. Trailing yield: 0.3%. Lower than top quartile of German dividend payers (3.6%). Lower than average of industry peers (1.1%). Valuation Update With 7 Day Price Move • Mar 08
Investor sentiment deteriorated over the past week After last week's 15% share price decline to €304, the stock trades at a forward P/E ratio of 37x. Average forward P/E is 31x in the Medical Equipment industry in Germany. Total returns to shareholders of 140% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €290 per share. Reported Earnings • Feb 18
Full year 2021 earnings: Revenues exceed analyst expectations Full year 2021 results: Revenue: €3.45b (up 48% from FY 2020). Net income: €318.9m (up 41% from FY 2020). Profit margin: 9.2% (in line with FY 2020). Revenue exceeded analyst estimates by 1.5%. Over the next year, revenue is forecast to grow 18%, compared to a 12% growth forecast for the industry in Germany. Valuation Update With 7 Day Price Move • Jan 10
Investor sentiment deteriorated over the past week After last week's 15% share price decline to €416, the stock trades at a forward P/E ratio of 57x. Average forward P/E is 36x in the Medical Equipment industry in Germany. Total returns to shareholders of 326% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €292 per share. Reported Earnings • Oct 22
Third quarter 2021 earnings released The company reported a solid third quarter result with improved earnings and revenues, although profit margins were flat. Third quarter 2021 results: Revenue: €897.7m (up 44% from 3Q 2020). Net income: €105.6m (up 55% from 3Q 2020). Profit margin: 12% (in line with 3Q 2020). Price Target Changed • Jul 26
Price target increased to €383 Up from €355, the current price target is an average from 17 analysts. New target price is 20% below last closing price of €480. Stock is up 78% over the past year. Reported Earnings • Jul 24
Second quarter 2021 earnings released The company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2021 results: Revenue: €838.1m (up 53% from 2Q 2020). Net income: €108.1m (up 219% from 2Q 2020). Profit margin: 13% (up from 6.2% in 2Q 2020). The increase in margin was driven by higher revenue. Reported Earnings • Apr 24
First quarter 2021 earnings released: EPS €1.20 The company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2021 results: Revenue: €791.1m (up 55% from 1Q 2020). Net income: €82.0m (up 78% from 1Q 2020). Profit margin: 10% (up from 9.1% in 1Q 2020). The increase in margin was driven by higher revenue. Upcoming Dividend • Mar 22
Upcoming Dividend of €0.70 Per Share Will be paid on the 31st of March to those who are registered shareholders by the 29th of March. The trailing yield of 0.2% is below the top quartile of German dividend payers (3.3%), and is lower than industry peers (1.0%). Price Target Changed • Feb 23
Price target raised to €331 Up from €247, the current price target is an average from 16 analysts. The new target price is 23% below the current share price of €432. As of last close, the stock is up 108% over the past year. Reported Earnings • Feb 20
Full year 2020 earnings released: EPS €3.31 (vs €2.29 in FY 2019) The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2020 results: Revenue: €2.34b (up 28% from FY 2019). Net income: €226.3m (up 44% from FY 2019). Profit margin: 9.7% (up from 8.6% in FY 2019). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 22% per year but the company’s share price has increased by 62% per year, which means it is tracking significantly ahead of earnings growth. Is New 90 Day High Low • Jan 30
New 90-day high: €370 The company is up 14% from its price of €325 on 30 October 2020. The German market is up 20% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Medical Equipment industry, which is up 19% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €189 per share. Price Target Changed • Nov 25
Price target raised to €247 Up from €217, the current price target is an average from 16 analysts. The new target price is 23% below the current share price of €320. As of last close, the stock is up 87% over the past year. Is New 90 Day High Low • Oct 22
New 90-day high: €331 The company is up 22% from its price of €271 on 24 July 2020. The German market is down 3.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Medical Equipment industry, which is down 1.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €173 per share. Is New 90 Day High Low • Oct 01
New 90-day high: €303 The company is up 22% from its price of €248 on 03 July 2020. The German market is up 1.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Medical Equipment industry, which is up 1.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €187 per share.